Efficacy and tolerability of fesoterodine versus tolterodine in older and younger subjects with overactive bladder: A post hoc, pooled analysis from two placebo-controlled trials

• Published in: Neurourology and urodynamics Vol. 31; no. 8; pp. 1258 - 1265
• Main Authors: DuBeau, Catherine E., Morrow, Jon D., Kraus, Stephen R., Creanga, Dana, Bavendam, Tamara
• Format: Journal Article
• Language: English
• Published: Hoboken Wiley Subscription Services, Inc., A Wiley Company 01.11.2012
• Subjects: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; antimuscarinic agents; Benzhydryl Compounds - adverse effects; Benzhydryl Compounds - therapeutic use; Cresols - adverse effects; Cresols - therapeutic use; Female; fesoterodine; Humans; Male; Middle Aged; Muscarinic Antagonists - adverse effects; Muscarinic Antagonists - therapeutic use; older persons; overactive bladder; patient-reported outcomes; Phenylpropanolamine - adverse effects; Phenylpropanolamine - therapeutic use; Quality of Life; randomized controlled trials; Randomized Controlled Trials as Topic; signs and symptoms; Surveys and Questionnaires; Time Factors; tolterodine; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder - drug effects; Urinary Bladder - physiopathology; Urinary Bladder, Overactive - diagnosis; Urinary Bladder, Overactive - drug therapy; Urinary Bladder, Overactive - physiopathology; Urinary Bladder, Overactive - psychology; Urinary Incontinence, Urge - diagnosis; Urinary Incontinence, Urge - drug therapy; Urinary Incontinence, Urge - physiopathology; Urinary Incontinence, Urge - psychology; Urination - drug effects; Young Adult

Aims To assess the efficacy and tolerability of fesoterodine 8 mg versus tolterodine extended release (ER) 4 mg in subjects with overactive bladder (OAB) stratified by age (<65, 65–74, and ≥75 years). Methods This was a post hoc analysis of data from two double‐blind trials. Subjects reporting ≥1...